Armed With Two Patents, Psycheceutical Plans To Transform Psychedelic Drug Delivery

Armed With Two Patents, Psycheceutical Plans To Transform Psychedelic Drug Delivery

Psycheceutical recently announced the approval of two of its patents that could revolutionize psychedelic medicine delivery systems. The technologies allow psychedelic drugs to bypass the stomach, liver and blood-brain barrier—making tinkering with certain psychedelic effects possible.

Psycheceutical’s patented delivery systems allow psychedelics such as psilocybin, ibogaine and ketamine to be delivered into the body without unwanted side effects and toxicity. 

Psychedelic concierge Mike “Zappy” Zapolin says while companies chase after ongoing research into the efficacy of psychedelics, drug delivery technology is where the real opportunity lies—which is why he joined Psycheceutical’s team as Chief Visionary Officer.

“Everybody else is fighting it out for psilocybin for weight loss or ibogaine for addiction, just trying to get clearances,” Zapolin says, “and I realized these delivery systems that already work in pharmaceuticals are really the Holy Grail for the medical establishment—and the government.”

What people really need is a psycheceutical, Zapolin says, which is the best of both worlds, psychedelic and pharmaceutical drugs. 

Psycheceutical’s first patent—its Janus particle solution—uses layered nanoparticles to target specific cells and deliver multiple medicines at different times and rates—developed after  groundbreaking research was conducted at the University of Michigan by Professor Dr. Anish Tuteja, who said it has “immense potential to transform the delivery of psychedelic therapies.”

NeuroDirect™ delivery system, Psycheceutical’s second patented technology, administers neuroactive compounds directly to nerve connections to the brain, bypassing the blood-brain barrier—which typically prevents the uptake of “most pharmaceuticals.”

“Psycheceutical’s technologies are about to revolutionize psychedelic drug delivery with the capability to eliminate the toxicity and hallucinogenic properties that are prevalent in psychedelic drugs,” CEO Chad Harman says.

He continued, “The safety and efficacy with which we can now deliver psychedelic medicine will break down the barriers to access and adoption of these incredible healing compounds.” Harman’s background in the cannabis industry prepared him for the commercial world of psychedelics.

When Zapolin learned about this new class of drugs, he knew that he had to get involved. “Because of this technology you can target the drug the way you want,” he says. “You can get it through the blood-brain barrier, so it can bypass the stomach, and the liver, which avoids degradation and toxicity. When that happens, you’re getting less of the medicine and more of the bioavailability.”

Many of the psychedelic compounds and drugs that are emerging could be delivered using Psycheceutical’s systems—psilocybin, 18-MC, ibogaine, ketamine, MDMA—in a psycheceutical format. The person takes less of the drugs, but with more bioavailability.

“The science is fantastic,” Zapolin says. “The Janus particles is really a nano-particle solution. It was developed at the University of Michigan. Dr. Tutija, who is on our board, developed this. What it is that is so revolutionary is it’s a way of using layered nanoparticles. By layering the nano-particles and putting the compound into the nanoparticles in order to be carried. If you were to take ketamine nasally, or through a sublingual or through a transdermal. Or if you were to take any other compound, be it psilocin, or MDMA, so really MAPS is going to want to deliver MDMA in a psycheceutical form.”

What’s really cool about Psycheceutical’s technologies, Zapolin says, is with the nano-particles, you can allow time-release. Multiple psychedelics could be delivered at the same time, or a complementary compound could be added. For instance, Psycheceutical could have ketamine released immediately, and then an hour later release CBG or CBD into the system. 

Zapolin explained that ketamine clinics are currently limited to low-dose lozenges that have to be taken hourly. With a psycheceutical, drugs could release ketamine or any other compound under time-release, a little bit every hour. 

“What we’re going to do at Psycheceutical  is actually take our funds and go through the FDA process of putting some of these complementary compounds together in a psycheceutical so that people can offer these as [conventional pharmaceutical] medicine.”

In some cases, you can take the psychedelic effect out of a compound.

For instance, when psilocybin is taken orally, it goes into your stomach, gets processed, and is converted to the compound psilocin. “We can deliver psilocin directly through the blood-brain barrier and the person wouldn’t have to sit there for an hour,” Zapolin shares. “We can tinker with whether it’s going to include a psychedelic effect in a lot of compounds.”

Zapolin acknowledged the voices of opposition surrounding the idea of gaining patents and intellectual property for drug delivery systems, but feels the future of psychedelic medicine is more important. Think of the possibilities.

nullPsycheceutical, Inc – State-Of-The-Art Psychedelic Delivery Technologies

https://newsminer.co

Leave a Reply

Your email address will not be published. Required fields are marked *